Voluntary Disclosure on the Approval of Clinical Trial for Inhaled Tuberculosis Vaccine (Adenovirus Type 5 Vector) in Indonesia

About this update from Cansino Biologics, Inc. Class A

Voluntary Disclosure on the Approval of Clinical Trial for Inhaled Tuberculosis Vaccine (Adenovirus Type 5 Vector) in Indonesia The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Cansino Biologics, Inc. Class A